医学临床研究
  2025年6月16日 星期一           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2021, Vol. 38 Issue (6): 890-892    DOI: 10.3969/j.issn.1671-7171.2021.06.024
  论著 本期目录 | 过刊浏览 | 高级检索 |
醒脑静联合依达拉奉治疗脑出血对患者VEGF、BNP及和肽素水平的影响
贾楠婕a, 冯俊杰b
河南省濮阳市安阳地区医院:a.神经内科;b.针灸科,河南 安阳 455000
Effect of Xingnaojing Combined with Edaravone on the Levels of VEGF, BNP and Copeptin in Patients with Cerebral Hemorrhage
JIA Nan-jie, FENG Jun-jie
Anyang District Hospital, Puyang City,Anyang Henan 455000
全文: PDF (1115 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨醒脑静联合依达拉奉治疗脑出血对患者血管内皮生长因子(VEGF)、脑钠肽(BNP)及和肽素水平的影响。【方法】本院收治的脑出血患者96例,根据治疗方法不同分为对照组和观察组。两组均给予常规治疗外,对照组患者采用醒脑静治疗,观察组患者采用醒脑静联合依达拉奉治疗。比较两组患者治疗后的临床疗效。【结果】观察组患者总有效率为95.83%(46/48),明显高于对照组的75.00%(36/48),且差异有显著性(P<0.05)。治疗前两组各指标水平比较差异均无显著性(P>0.05)。治疗后,两组内皮素(ET)、VEGF、BNP、和肽素以及铁蛋白(SF)、一氧化氮(NO)、丙二醛(MDA)水平均低于治疗前(P<0.05),且观察组低于对照组(P<0.05)。治疗前,两组神经功能缺损量表(NIHSS)评分、蒙特利尔认知评估量表(MoCA)评分及日常生活活动量表(ADL)评分比较差异均无显著性(P>0.05)。治疗后,两组NIHSS评分低于治疗前,MoCA、ADL评分高于治疗前,且观察组治疗后NIHSS、MoCA、ADL评分优于对照组(P<0.05)。【结论】醒脑静联合依达拉奉治疗可提高脑出血的疗效,降低患者BNF、和肽素、SF、NO、MDA水平,改善患者神经功能,值得临床推广运用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
贾楠婕
冯俊杰
关键词 脑出血/治疗安替比林/类似物和衍生物利钠肽,脑血管内皮生长因子A肽类    
Abstract:【Objective】To analyze the effect of Xingnaojing combined with edaravone on the levels of vascular endothelial growth factor (VEGF), brain natriuretic peptide (BNP) and copeptin in patients with cerebral hemorrhage. 【Methods】A total of 96 patients with cerebral hemorrhage were selected and divided into the control group and the observation group according to different treatment methods. Both groups were given conventional treatments. Patients in the control group were treated with Xingnaojing alone, while patients in the observation group were treated with Xingnaojing assisted by edaravone. The clinical efficacy of the two groups were analyzed after treatment.【Results】The total effective rate of patients in the observation group was 95.83% (46/48), which was higher than that of the control group 75.00% (36/48, P<0.05). There was no significant difference in the levels of indicators between the two groups before treatment (P>0.05). After treatment, the levels of ET, VEGF, BNP, copeptin, SF, NO, and MDA in the two groups were lower than those before treatment; and the above indicators in the observation group were lower than those in the control group after treatment. The difference was statistically significant (P<0.05). Before treatment, there was no statistically significant difference between the two groups in terms of of NIHSS, MoCA (the Montreal cognitive assessment scale), and ADL (activity of daily living scale) scores (P>0.05). After treatment, the NIHSS scores of the two groups were lower than those before treatment, and MoCA and ADL scores were higher than those before treatment. The NIHSS, MoCA and ADL scores of the observation group after treatment were better than those of the control group (P<0.05). 【Conclusion】Xingnaojing combined with edaravone therapy can improve the efficacy of cerebral hemorrhage, reduce the levels of BNF, copeptin, SF, NO, and MDA in patients, and improve the neurological function of patients. It is worthy of clinical application.
Key wordsCerebral Hemorrhage/TH    Antipyrine/AA    Natriuretic Peptide, Brain    Vascular Endothelial Growth Factor A    Peptides
收稿日期: 2020-01-02     
中图分类号:  R743.34  
引用本文:   
贾楠婕, 冯俊杰. 醒脑静联合依达拉奉治疗脑出血对患者VEGF、BNP及和肽素水平的影响[J]. 医学临床研究, 2021, 38(6): 890-892.
JIA Nan-jie, FENG Jun-jie. Effect of Xingnaojing Combined with Edaravone on the Levels of VEGF, BNP and Copeptin in Patients with Cerebral Hemorrhage. JOURNAL OF CLINICAL RESEARCH, 2021, 38(6): 890-892.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.06.024     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I6/890
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn